Theratechnologies Inc T.TH

Wino is MIA?

[Lee430]

I am sure missing Wino’s sage contribution’s :-<  has he banished himself to the wine cellar in his despair over the SP? Or maybe he doubled down and is now over 10% ownership, sooo insider status maybe?

Could he be consulting Thera’s board or maybe replacing one of the two new board members who were almost voted out?

If your still out their Wino I hope all is well with you and your family and have much appreciated your contribution to this board.

[SPCEO1]

Also trusting that JFM is having one of his good weeks as well.

[Wino115]

Thanks for checking in, all is fine and just enjoying the summer.  I am focused on both how they have helped themselves to get to break even by cutting out $5mil in costs, which they frankly should have done earlier as a safety net, and on developments around SZ. It not worth commenting a lot on anything except whatever hard facts they present around the new trial, and that will come about

[jfm1330]

Same for me, I did not comment because there is nothing interesting to comment about. The story is repeating itself with Thera, and Levesque looks more and more like a new John Huss. He is now doing the same thing Huss did back around 2011, laying off R&D employees to cover his failures as CEO. So speciality pharmacies were expecting a higher demand with Egrifta and Trogarzo, but thanks to our

[Mannequin]

We must have closure on some partners, joint R&D projects or a rapid drug acquisition to stimulate sales.  What are they doing?  I suspect the internal sales team is presently busy lowering their golf handicap this summer. Creating an internal sales force was only a good thing if they are swamped. Not just busy but swamped. We brought all the costs in house, but for what?  

[SPCEO1]

If some closure on one or more of those issues is going to happen in the short term, it likely would happen before the 7/28 date to sort out the net liquidity isdue. Now, THTX does not need $20 million to operate the company so it is possible Marathon will just up their interest rate and let it be. Also, the sales team is generating prescription growth, but translating that into actual sales is

[PinnacleX]

Got this  jfm1300 guy putting out these posts how he doesnt trust the management team,  lol ya I ve been saying that for 4 years now.  

[SPCEO1]

I will comment on one thing you said. According to the company, no R&D associated with cancer were cut.

[jfm1330]

No R&D associated with the clinical trial, that's not R&D lab employees. It's impossible for them given the small size of the company to save 5.5 M$ and not touching the clinical side without slashing in the lab scientists. That's what they did in 2012, the scientists that worked on and developed the F2, F4 and F8 formulations were laid off and they slept on those formulations

[scarlet1967]

"As such, in addition to reducing R&D activities that were already planned for the latter part of '23 and full year '24, we are implementing an additional $5.5 million reduction in R&D annualized spending." Again they haven't clarified who goes, which programs get effected but this reduction is "additional" to anticipated reductions of R&D activities

[SPCEO1]

I was thinking the same thing but that is what I was told. I am sure how they defined their terms when saying that could differ from what I was assuming. But they indicated cancer R&D efforts escape the scalpel.